引用次数
引用: 11,849
H-指数: 40
I10-指数 : 101
出版物: 353
Behandlung des fortgeschrittenen Prostatakarzinoms – eine interdisziplinäre Empfehlung
Aurelius Omlin* , Martin Spahn* , Jörg Beyer , Daniel Eberli
Praxis Journal of Philosophy 107 ( 19) 1043 -1051
2018
Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.
Cyrill Rentsch , Christian Rothermundt , Silke Gillessen , Anja Lorch
Swiss Medical Weekly 140 ( 2526) 356 -369
20
2010
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Clemens B. Caspar , Pierre Bohanes , Roger von Moos , Beat Thürlimann
BMC Cancer 21 ( 1) 1 -9
2021
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3).
Ugo De Giorgi , Pia Paffenholz , Axel Heidenreich , Christoph Oing
World Journal of Urology 1 -8
2021
Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.
Ulf Petrausch , Martin Spahn , Julian Schardt , Nicolas Mach
Journal of Clinical Oncology 39 430 -430
9
2021
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
Matthias Schwenkglenks , Roger von Moos , Silke Gillessen , Beat Thürlimann
Swiss Medical Weekly 151 ( 0910)
2021
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium
Ugo De Giorgi , Peter Grimison , Robert A Huddart , Jourik A Gietema
Journal of Clinical Oncology 39 ( 14) 1553 -1562
2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
Daniel P. Petrylak , Johann S. de Bono , Anton I. Rosenbaum , Richard Cathomas
Clinical Cancer Research
2021
Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.
Aurelius Gabriel Omlin , Gedske Daugaard , Avivit Peer , Hermann Reichegger
Journal of Clinical Oncology 34 ( 15_suppl) 5057 -5057
5
2016
A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
Mark T. Fleming , Richard Cathomas , Daniel Peter Petrylak , Judy Sing-Zan Wang
Journal of Clinical Oncology 35
2017
Improved survival of older patients with multiple myeloma in the era of novel agents
Ulrich J. M. Mey , Christoph Leitner , Christoph Driessen , Richard Cathomas
Hematological Oncology 34 ( 4) 217 -223
17
2016
Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma.
Alexandros Papachristofilou , Jens Bedke , Stefanie Hayoz , Natalie Fischer
Journal of Clinical Oncology 38 ( 6_suppl) 405 -405
1
2020
Prognostic impact of LDH and HCG levels in marker-positive seminomas.
Christoph Alexander Seidel , Gedske Daugaard , Tim Nestler , Alexey Tryakin
Journal of Clinical Oncology 38 ( 6_suppl) 392 -392
3
2020
Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).
Richard Cathomas , Ulf Petrausch , Stefanie Hayoz , Martina Schneider
Journal of Clinical Oncology 38 ( 6_suppl) 499 -499
6
2020
Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression.
Emmanuelle Kempf , Nicolas Penel , Christophe Tournigand , Pablo Gajate
Journal of Clinical Oncology 38 527 -527
1
2020
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.
Johann S. De Bono , Mark T. Fleming , Judy Sing-Zan Wang , Richard Cathomas
Journal of Clinical Oncology 38 ( 6_suppl) 99 -99
1
2020
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study
Michael Mark , Dirk Klingbiel , Ulrich Mey , Ralph Winterhalder
Clinical Genitourinary Cancer 17 ( 2)
8
2019
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Aurelius Omlin , Oliver Sartor , Christian Rothermundt , Richard Cathomas
Clinical Genitourinary Cancer 13 ( 4)
23
2015
Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program
Ralph Winterhalder , Andreas Barth , Walter Mingrone , Catrina Uhlmann Nussbaum
Clinical Genitourinary Cancer 15 ( 3) e315 -e323
4
2017
Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Deborah R. Vogt , Frank Stenner , Nadja Sandmeier , Sacha I. Rothschild
Clinical Genitourinary Cancer 16 ( 4)
2018